Tevogen Bio Holdings Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TVGN Nasdaq 2830 tevogen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Are Analysts Optimistic? - Jul 2nd, 2025 7:30 am
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters - Jun 30th, 2025 12:28 pm
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery - Jun 18th, 2025 6:30 am
Tevogen expands headquarters in Warren, New Jersey - Jun 10th, 2025 7:15 am
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives - Jun 9th, 2025 7:00 am
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships - May 30th, 2025 9:01 am
Tevogen Peports Plans to Increase the Target Population for TVGN 489 - May 25th, 2025 4:19 pm
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow - May 23rd, 2025 1:49 pm
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting - May 22nd, 2025 11:21 am
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - May 12th, 2025 6:00 am
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest - May 2nd, 2025 1:45 pm
Biotech Alert: Searches spiking for these stocks today - May 1st, 2025 10:15 am
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment - Apr 30th, 2025 1:49 pm
Tevogen sees launch year oncology business revenue $1B - Apr 29th, 2025 2:50 pm
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts - Apr 29th, 2025 11:48 am
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald - Apr 29th, 2025 6:00 am
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion - Apr 28th, 2025 2:36 pm
Tevogen Bio Announces 2025 Annual Meeting - Apr 25th, 2025 12:33 pm
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility - Apr 17th, 2025 12:54 pm
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction - Apr 15th, 2025 12:03 pm